Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05604170 · ClinicalTrials.gov registry record · Phase 3
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
A Phase 3 study, sponsored by Marinus Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 117
- Enrollment target
NCT05604170 is a Phase 3 study that was terminated before completion, run by Marinus Pharmaceuticals. The registered enrollment target is 117 participants.
The verdict
NCT05604170, a Phase 3 study, was terminated before completion, sponsored by Marinus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 117 participants
- Enrollment target
Study Summary
This is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated in either Study 1042-TSC-3001 or Study 1042-TSC-2001
Interventions
- DRUG Ganaxolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2022-05-16 |
| Est. Completion | 2025-04-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05604170
The ClinicalTrials.gov registry entry for NCT05604170 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marinus Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ganaxolone is the first listed.
NCT05604170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05604170 about?
NCT05604170 is a clinical study titled "Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy". This is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated in either Study 1042-TSC-3001 or Study 1042-TSC-2001
What is the current status of trial NCT05604170?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 117 participants. The study started on 2022-05-16. Estimated completion is 2025-04-02.
What interventions are being tested in trial NCT05604170?
The interventions under investigation include: Ganaxolone (DRUG).
Who is sponsoring clinical trial NCT05604170?
This trial is sponsored by Marinus Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.